<?xml version="1.0" encoding="UTF-8"?>
<p>The iron chelation therapy has modified the life expectancy of thalassemia patients; mortality data show a decrease in causes of death due to heart disease and an increase in liver disease (Prati et al., 
 <xref rid="B33" ref-type="bibr">1998</xref>, 
 <xref rid="B32" ref-type="bibr">2004</xref>; Borgna-Pignatti et al., 
 <xref rid="B5" ref-type="bibr">2004</xref>; Agas et al., 
 <xref rid="B2" ref-type="bibr">2008</xref>). Iron overload and HCV infection have been established to be risk factors for thalassemia patients to develop liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (Di Marco et al., 
 <xref rid="B9" ref-type="bibr">2008</xref>; Voskaridou et al., 
 <xref rid="B45" ref-type="bibr">2012</xref>; Borgna-Pignatti et al., 
 <xref rid="B4" ref-type="bibr">2014</xref>; Chung et al., 
 <xref rid="B7" ref-type="bibr">2015</xref>; Moukhadder et al., 
 <xref rid="B25" ref-type="bibr">2017</xref>; Hodroj et al., 
 <xref rid="B12" ref-type="bibr">2019</xref>). Only 15–25% of the infected subjects can eliminate the infection alone. The remaining 75–85% of them make the infection chronic, developing cirrhosis that can be complicated by liver failure and hepatocellular carcinoma. In several studies from different population of thalassemic patients (United States, Italy and Greece) the prevalence of cirrhosis ranged from 10 to 20% and the incidence of HCC in thalassemia patients was progressively increasing (Voskaridou et al., 
 <xref rid="B45" ref-type="bibr">2012</xref>; Borgna-Pignatti et al., 
 <xref rid="B4" ref-type="bibr">2014</xref>; Chung et al., 
 <xref rid="B7" ref-type="bibr">2015</xref>; Moukhadder et al., 
 <xref rid="B25" ref-type="bibr">2017</xref>; Rumi et al., 
 <xref rid="B43" ref-type="bibr">2018</xref>; Hodroj et al., 
 <xref rid="B12" ref-type="bibr">2019</xref>). These data have made an intervention to eradicate HCV infection more urgent.
</p>
